SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Assertio Holdings, Inc. (ASRT) (CIK 0001808665) (ASRT) — Jun 9, 2023

Assertio Holdings, Inc. (ASRT) (CIK 0001808665)
Date: June 9, 2023 · CIK: 0001808665 · Accession: 0000000000-23-006223

Regulatory Compliance Financial Reporting Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-272355

Date
June 9, 2023
Author
Daniel Peisert
Form
UPLOAD
Company
Assertio Holdings, Inc. (ASRT) (CIK 0001808665)

Letter

United States securities and exchange commission logo June 9, 2023 Daniel Peisert President and Chief Executive Officer Assertio Holdings, Inc. 100 South Saunders Rd., Suite 300 Lake Forest, IL 60045 Re:Assertio Holdings, Inc. Registration Statement on Form S-4 Filed June 2, 2023 File No. 333-272355 Dear Daniel Peisert: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jonathan Sarna, Esq.

Show Raw Text
United States securities and exchange commission logo
June 9, 2023
Daniel Peisert
President and Chief Executive Officer
Assertio Holdings, Inc.
100 South Saunders Rd., Suite 300
Lake Forest, IL 60045
Re:Assertio Holdings, Inc.
Registration Statement on Form S-4
Filed June 2, 2023
File No. 333-272355
Dear Daniel Peisert:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Jonathan Sarna, Esq.